Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma

Hepatology. 2023 Jan 1;77(1):E5-E6. doi: 10.1002/hep.32672. Epub 2022 Sep 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Hepatocellular*
  • Hepatitis B virus / physiology
  • Hepatitis B* / drug therapy
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Liver Neoplasms*
  • Virus Activation

Substances

  • Immune Checkpoint Inhibitors